Calypte und die Zeit nach AIDS2004 in Bangkok
Seite 7 von 203 Neuester Beitrag: 19.01.06 14:27 | ||||
Eröffnet am: | 05.07.04 15:03 | von: Kade_I | Anzahl Beiträge: | 6.056 |
Neuester Beitrag: | 19.01.06 14:27 | von: Der_wahre_. | Leser gesamt: | 186.733 |
Forum: | Hot-Stocks | Leser heute: | 91 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 4 | 5 | 6 | | 8 | 9 | 10 | ... 203 > |
Calypte Biomedical and Earvin 'Magic' Johnson Commemorate World AIDS Day December 1st
ALAMEDA, Calif., Dec. 2 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (BULLETIN BOARD: CYPT) , the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, today announced that Calypte's Chairman Tony Cataldo and "Magic" Ervin Johnson spent December 1st, World AIDS Day, speaking on the importance of HIV/AIDS testing.
"World AIDS Day is the ideal time for everyone to commit to being tested," said Johnson. "It's a day when we can take on the rampant spread of HIV one person at a time," he added. Calypte's Chairman Anthony Cataldo stated, "Early detection can significantly alter the quality of life, and can help prevent the spread of HIV and can ultimately save lives."
Magic Johnson first appeared on NBC's Today Show followed by an interview on BET and ABC radio. Both Mr. Cataldo and Mr. Johnson appeared on MSNBC and Fox News, Your World with Neal Cavuto to discuss the company and highlight the need for HIV/AIDS testing.
To access these events please go to the company's web site at http://www.calypte.com/ About The Magic Johnson Foundation
The Magic Johnson Foundation was established in 1991 as a single-disease organization that worked to raise funds for community-based organizations dealing with HIV/AIDS education and prevention programs. The Foundation has since responded to the growing need to address all aspects of our youth's lives by expanding its mission. This expanded mission emphasizes the Foundation's focus on supporting community-based organizations and developing programs that serve the health, educational and social needs of those residing in inner-city communities. In addition, the Foundation has made a strong commitment to raise awareness about many of the health and social concerns that threaten under-served communities.
About Calypte Biomedical
Calypte Biomedical Corporation, headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western Blot test. The Company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly.
Last:
Change:
+ Volume:
375,600
Das sind knapp 250.000 $, wer stellt hier ne Order in dieser Summe rein, sicherlich kein Kleinanleger.
Topic: Preliminary evaluation of urine EIA for detection of antibodies to HIV - 1 in urine specimens of Thai HIV infected patients
By: S Kohreanudom1, S Dettrairat2, K Faithong2
1Bureau of AIDS, TB and STI, Nonthaburi, Thailand; 2Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai , Thailand
Background: Testing of antibodies to HIV - 1 with blood specimens is the gold standard method for identifying HIV infected persons. Urine specimens may be alternative to blood specimens and facilitate surveillance of HIV infection.
Methods: Urine specimens were randomly collected from 100 Thai HIV-1 infected patients being treated with ARV drugs and 59 normal healthy persons. Specimens were aliquot and kept at 4-10 °C until testing. All urine specimens were tested for antibodies to HIV-1 by Calypte HIV-1 urine EIA as the test instruction. Moreover, all urine specimens were also tested for antibodies to HIV-1 with simple particle agglutination test for blood specimens with slightly modified procedure. Specimens giving discordance results by 2 methods were repeatedly tested with the same specimens. Sensitivity and specificity were calculated using the final test results compared to HIV status of the subjects.
Results: Urine EIA gave sensitivity of 98% (98/100) with urine specimens collected from HIV infected patients. By testing with urine specimens collected from normal healthy persons, the specificity was 100 % (59/59). Unsurprisingly, particle agglutination test for blood specimens, showed lower in both sensitivity (86%,86/100) and specificity (98%, 58/59) than urine EIA.
Conclusion: By using specimens from Thai HIV-infected patients, urine EIA has high sensitivity and specificity. Testing urine specimens with urine EIA may be benefit for surveillance of HIV infection in Thailand.
Hier nochmal ein Auszug der Nachricht vom 25.05.04 welche
den Kursanstieg ausgelöst hat:
Calypte hat vorher Pläne verkündet, um seine schnellen Tests in China und in Thailand herzustellen. Der Thailand Service wird erwartet, um in der Produktion zu sein bis zum August von 2004. China wird erwartet, in das 4. Viertel von 2004 später zu folgen.
(AltaVista übersetzt)
Ich gehe davon aus das die ihre Pläne einhalten wollen.
Sollte die entsprechende News dazu kommen,das produziert wird,
gibt es für den Kurs nur eine Richtung = $ 1 usw.
Vielleicht kommt diese News schon während der Konferenz.
@all: Wie seht Ihr das?
Wollen wir hoffen,das alles so eintrifft,wie wir das möchten.
Ich stell mal einen Link ein,schau Dir das mal an.
http://www.pinksheets.com/quote/...26provider%3DEDGARnews&symbol=CYPT
Gibt mir etwas denken!
Von: Tim Clemensen
Gesendet: Montag, 12. Juli 2004 13:23:53
An: ---
Betreff: RE: Calypte rapid tests
The company will announce the production schedule and product roll out through a press release in the near future. This week they are in Bangkok for the World Aids convention.
Regards,
Tim Clemensen
Vice President
Rubenstein Investor Relations
1345 Avenue of the Americas
New York, NY 10105
Tel. 212.843.9337
-----Original Message-----
From: ---
Sent: Sunday, July 11, 2004 6:33 PM
To: tclemensen@rubensteinir.com
Subject: Calypte rapid tests
Dear Mr. Clemensen,
please inform me about my following question:
When will the production of the new Calypte rapid tests will start at Pacific-Biotech-Factory in Thailand and how many tests are planned to be produced per year. Or has it been started already ? When will the first Calypte rapid tests be available to buy ?
Thanks in advance for your fast answers.
Sincerely
Yours
---
(Germany)